These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination. Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754 [TBL] [Abstract][Full Text] [Related]
29. Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides. Franke ED; Corradin G; Hoffman SL J Immunol; 1997 Oct; 159(7):3424-33. PubMed ID: 9317141 [TBL] [Abstract][Full Text] [Related]
30. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity. Woo SJ; Kim CH; Park MY; Kim HS; Sohn HJ; Park JS; Kim HJ; Oh ST; Kim TG Cancer Sci; 2008 May; 99(5):1034-9. PubMed ID: 18294279 [TBL] [Abstract][Full Text] [Related]
31. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. Garbi N; Arnold B; Gordon S; Hämmerling GJ; Ganss R J Immunol; 2004 May; 172(10):5861-9. PubMed ID: 15128765 [TBL] [Abstract][Full Text] [Related]
32. Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer. Lubaroff DM; Karan D; Andrews MP; Acosta A; Abouassaly C; Sharma M; Krieg AM Vaccine; 2006 Aug; 24(35-36):6155-62. PubMed ID: 16876291 [TBL] [Abstract][Full Text] [Related]
33. Immunostimulatory CpG motifs induce CTL responses to HIV type I oligomeric gp140 envelope protein. Rao M; Matyas GR; Vancott TC; Birx DL; Alving CR Immunol Cell Biol; 2004 Oct; 82(5):523-30. PubMed ID: 15479438 [TBL] [Abstract][Full Text] [Related]
34. [CpG oligodeoxynucleotide enhances humoral and cellular immune responses against HBsAg in mice]. Zhou Z; Chen WS; Yao JL Zhonghua Nei Ke Za Zhi; 2003 Sep; 42(9):640-2. PubMed ID: 14514394 [TBL] [Abstract][Full Text] [Related]
35. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen. Tewary P; Sukumaran B; Saxena S; Madhubala R Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055 [TBL] [Abstract][Full Text] [Related]
36. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Wingender G; Garbi N; Schumak B; Jüngerkes F; Endl E; von Bubnoff D; Steitz J; Striegler J; Moldenhauer G; Tüting T; Heit A; Huster KM; Takikawa O; Akira S; Busch DH; Wagner H; Hämmerling GJ; Knolle PA; Limmer A Eur J Immunol; 2006 Jan; 36(1):12-20. PubMed ID: 16323249 [TBL] [Abstract][Full Text] [Related]
37. Induction of antigen-specific cytotoxic T lymphocytes by immunization with negatively charged soluble antigen through scavenger receptor-mediated delivery. Yamasaki Y; Ikenaga T; Otsuki T; Nishikawa M; Takakura Y Vaccine; 2007 Jan; 25(1):85-91. PubMed ID: 16956699 [TBL] [Abstract][Full Text] [Related]
38. Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do. Najar HM; Dutz JP Eur J Immunol; 2007 Aug; 37(8):2242-56. PubMed ID: 17634951 [TBL] [Abstract][Full Text] [Related]
39. Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological analysis of vaccine efficacy. Masuko K; Wakita D; Togashi Y; Kita T; Kitamura H; Nishimura T Immunol Lett; 2015 Jan; 163(1):102-12. PubMed ID: 25479286 [TBL] [Abstract][Full Text] [Related]